Product Description
A pegylated form of human synthetic C-peptide (CBX129801) has been developed to extend the half-life of the native peptide and is undergoing clinical investigation as replacement therapy to treat diabetic peripheral neuropathy.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cebix
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 1 Diabetes|Peripheral Nervous System Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2012-001246-17 |
2012-001246-17 | P2 |
Completed |
Type 1 Diabetes |
2014-12-02 |
2022-03-13 |
||
NCT01681290 |
CBX129801-DN-201 | P2 |
Completed |
Peripheral Nervous System Diseases|Type 1 Diabetes |
2014-11-01 |
2019-03-19 |
Treatments |
|
NCT01293461 |
CBX129801-PK-101 | P2 |
Completed |
Type 1 Diabetes |
2012-08-01 |
2019-03-19 |
Treatments |